- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02803242
COPD Patient-Powered Research Network (COPD PPRN)
March 8, 2022 updated by: COPD Foundation
The COPD Patient-Powered Research Network (COPD PPRN) is a patient research registry with the goal of enrolling 75,000 or more COPD patients and those at risk who are willing to share their heath information over several years and participate in research.
The COPD PPRN has built an online platform to allow volunteers to enroll electronically, complete surveys, be contacted about studies they qualify for and become connected to COPD resources.
The goal of the registry is to speed research to find better treatments for COPD and ultimately a cure.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
75000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gretchen M McCreary, MA
- Phone Number: 396 866-731-2673
- Email: gmccreary@copdfoundation.org
Study Contact Backup
- Name: Elisha Malanga
- Phone Number: 309 866-731-2673
- Email: emalanga@copdfoundation.org
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20001
- Recruiting
- COPD Foundation
-
Contact:
- Gretchen M McCreary, MA
- Phone Number: 396 866-731-2673
- Email: gmccreary@copdfoundation.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
English speaking individuals who are over the age of 18 and have a diagnosis of COPD or fall into one of the following categories that put's them at risk - current or former smoker, environmental/occupational exposure, family history of respiratory disease or symptomatic of respiratory disease.
Description
Inclusion Criteria:
- 18 years or older that says yes to one of the following:
- COPD diagnosis
- Current or former smoker
- Family history of respiratory disease
- Symptomatic of respiratory disease
Exclusion Criteria:
- Non-English speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Patient Reported Outcome Measurement Information System-29 (PROMIS-29)
Time Frame: 15 years
|
15 years
|
|
COPD Assessment Test (CAT)
Time Frame: 15 years
|
15 years
|
|
Modified Medical Research Council (MMRC) Dyspnea Scale
Time Frame: 15 years
|
15 years
|
|
Charlson Comorbidity Index (CCI)
Time Frame: 15 years
|
15 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Anticipated)
January 1, 2025
Study Completion (Anticipated)
January 1, 2030
Study Registration Dates
First Submitted
June 14, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (Estimate)
June 16, 2016
Study Record Updates
Last Update Posted (Actual)
March 10, 2022
Last Update Submitted That Met QC Criteria
March 8, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COPDPPRN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonaryUnited States, Australia, Austria, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
-
Rabin Medical CenterUnknownPatients With Advanced Homogeneous EmphysemaIsrael
-
Aeris TherapeuticsWithdrawnAdvanced Upper Lobe Predominant Emphysema
Clinical Trials on Patient Reported Outcomes
-
University Hospital TuebingenNational Center for Tumor Diseases (NCT), University Hospital Heidelberg,... and other collaboratorsCompletedBreast Cancer MetastaticGermany
-
Massachusetts General HospitalCompletedDepression | Mood Disorders | Bipolar Disorder | Major Depressive DisorderUnited States
-
Stanford UniversityAstraZenecaCompletedCardiovascular Diseases | Vascular Diseases | Arteriosclerosis | Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Vascular Diseases | Atherosclerosis | Intermittent Claudication | Signs and Symptoms | Patient ComplianceUnited States
-
Medical University of ViennaRecruitingSpeech Disorders | Assessment, Self | Measurement, Psychological StressAustria
-
Seoul National University HospitalSamsung Medical Center; Korea University Anam Hospital; Catholic Medical Center...Enrolling by invitationLymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Marginal Zone Lymphoma(MZL) | Waldenström Macroglobulinemia (WM)South Korea
-
Rennes University HospitalCompleted
-
Nantes University HospitalCompletedKidney Transplantation | Renal InsuffiencyFrance
-
Wei XiaopingRecruiting
-
University of BernCompletedTooth Loss | Patient Satisfaction | Patient Acceptance of Health Care | Bone Graft; ComplicationsSwitzerland
-
Fraser Orthopaedic Research SocietyRecruiting